Views & Analysis Huge scale of Brexit threat to Europe’s medicines supplies r... New survey reveals the huge task facing pharma in keeping medicines moving around Europe after Brexit.
Views & Analysis PRIME movers: taking stock of the EMA's scheme Taking stock of one PRIME, of the EMA’s flagship market access initiatives.
Views & Analysis New UK law to control generic drug prices - implications for... The aims and implications of the Health Service Medical Supplies (Costs) Act 2017.
News UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face